Q3 results on Feb 11, 2016
Natco Pharma Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on February 11, 2016, inter alia, to consider the following:1. The unaudited financial Results for the quarter and nine months ended December 31, 2015 and related matters (Q3).2. To consider Interim Dividend, if any, for the financial year 2015-16 and related matters etc.... Shareholding for the Period Ended December 31, 2015
Natco Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2015. For more details, kindly Click here Natco Pharma surges on signing licensing agreement for Daclatasvir
The stock surged 7% to Rs 544 on the BSE. NATCO Announced Licensing Agreement for Daclatasvir
Natco Pharma Ltd has informed BSE regarding a Press Release dated January 21, 2016 titled "NATCO Announced Licensing Agreement for Daclatasvir". Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015
Natco Pharma Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended December 31, 2015, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Limited Review Report for Sept 30, 2015
Natco Pharma Ltd has submitted to BSE a Copy of the Limited Review Report for the period ended September 30, 2015. Differentiated pipeline to boost Natco Pharma
Strengthening of oncology and hepatitis portfolio in India and strong US pipeline to help company sustain rapid pace of growth
Celgene settles Revlimid patent litigation with Natco
Celgene says it has settled a litigation with Natco Pharma and its US partner, Arrow International Ltd, relating to patents of cancer drug Revlimid NATCO announces REVLIMID Settlement with Celgene
Natco Pharma Ltd has submitted to BSE a copy of Press Release dated December 23, 2015 titled "NATCO announces REVLIMID Settlement with Celgene". NATCO receives generic Ledipasvir + Sofosbuvir approval for India
Natco Pharma Ltd has informed BSE regarding a Press Release dated December 15, 2015 titled "NATCO receives generic Ledipasvir + Sofosbuvir approval for India".